

PROVISIONAL PROGRAMME AND CALL FOR ABSTRACTS

ILCA 2017

INTERNATIONAL LIVER CANCER ASSOCIATION

11th Annual Conference

15 ▶ 17 September 2017

Seoul, South Korea
Grand Hyatt Seoul

ILCA

International Liver Cancer Association

KEY DATES

ABSTRACT SUBMISSION
31 March 2017

EARLY REGISTRATION
5 June 2017

LATE REGISTRATION
28 August 2017

ONSITE FEE
As of 29 August 2017

The international
multidisciplinary
forum for liver
cancer experts
around the latest
innovations in
research and care

CONFERENCE HIGHLIGHTS:

- State-of-the-Art Lectures
- Cutting Edge Symposia
- General Sessions
- Interactive Luncheon Workshops
- e-Poster Viewing Tour
- Industry Exhibition
- Networking Breaks and Reception
- Pre-Conference Workshop

Register now online

www.ilca2017.org


The Conference

Priming Knowledge in Liver Cancer across Disciplines

ILCA is pleased to bring its Annual Conference to the vibrant and captivating city of Seoul where traditional meets modernity.

ILCA Annual Conference is the leading scientific meeting in the liver cancer field connecting hundreds of international participants from all related disciplines to exchange the latest innovation, research and best practices in general sessions, symposia, workshops and networking sessions.

ILCA offers a programme with a multidisciplinary and transversal approach with the objective to encourage and stimulate scientific debate and networking between liver cancer experts from all regions.



2016 Attendee Breakdown

Who should Attend?

Clinical, translational and basic researchers, physicians and allied professionals across liver cancer related disciplines will convene at ILCA 2017 in Seoul to share best practices and findings, making this event the premier forum for advancing research in the pathogenesis, prevention, and treatment of liver cancer.

Contributions from Participants

All participants are invited to make submissions for adjudication by an Abstract Review Committee. The Committee will accept or reject the work according to the relevance to ILCA, objectivity of statements, suitability of methods, conclusions confirmed by objective results, scientific value, originality of work and overall impression. Selected submissions considered to have especially broad appeal will be assigned to General Sessions for presentation as Oral Communications. All other accepted submissions will be presented in e-Poster format. The e-Poster viewing tour will be opened by one of the ILCA prominent scientists and be partly dedicated to the top scored abstracts within each category, presented in paper board poster format.

How to Submit an Abstract

Abstracts may only be submitted electronically through the conference website www.ilca2017.org. The abstract submissions open on 16 January 2017. Abstracts should address all aspects of liver cancer with a clear emphasis on maximizing focus, exchange and results. **The deadline for abstract submissions is 31 March 2017.** Please visit www.ilca2017.org to review abstract categories and submission guidelines.

Speakers Information



Massimo G. Colombo, MD (Italy)

Massimo G. Colombo is Professor of Gastroenterology at the University of Milan, Italy. His research interests include the diagnosis and treatment of viral hepatitis, liver transplantation and liver cancer. A member of many professional societies including EASL, AASLD and several Italian societies, he is the recipient of numerous awards including the 2010 EASL Recognition Award for outstanding medical and scientific contributions, as well as the Italian Association for the Study of the Liver Distinguished Service Award and the German Gastroenterology Society Thannhauser Medal Award.



Norihiro Kokudo, MD, PhD (Japan)

Norihiro Kokudo is the Professor and Chairman at Hepato-Biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, The University of Tokyo Hospital. Dr. Kokudo has been conducting a number of research projects on surgical treatment of HCC, colorectal liver metastases, and living donor liver transplantation. As the Chairman of the Guideline Committee, he compiled the 3rd version of Japanese Clinical Practice Guidelines for HCC in 2013.



Joong-Won Park, MD, PhD (Republic of Korea)

Joong-Won Park is a Principal Scientist of the National Cancer Center, Korea, and a Professor of Graduate School of Cancer Science and Policy, NCC Korea. He was the Head of the Center for Liver Cancer, NCC, Korea from 2002 to 2010, and was the Head of Translational and Clinical Research at the National Cancer Center Research Institute from 2008 to 2011. Dr. Park completed his Medical degree at Seoul National University in 1984 followed by a residency in Internal Medicine and a Clinical Fellowship in Hepatology at Seoul National University Hospital.

The Programme

- General Session
- Symposium
- State-of-the-Art Lecture
- Industry Symposium
- Workshop

Thursday, 14 September 2017

- 13:00 – 17:30 **Pre-Conference Workshop on Intermediate Stage Hepatocellular Carcinoma**
The pre-conference workshop is subject to an additional registration. To attend this workshop, full conference registration is compulsory.

Friday, 15 September 2017

- 08:00 – 09:30 **ILCA Symposium 1: Epidemiology in Hepatocellular Carcinoma**
- **Global Evolution of HCC Epidemiology in Western Countries**
Katheryne A. McGlynn, PhD (USA)
 - **Modification of HCC Epidemiology in Asia**
Chien-Jen Chen, PhD (Taiwan)
 - **Impact of Antiviral Therapies on HCC Epidemiology**
Massimo Colombo, MD, PhD (Italy)
 - **Genomics to Identify New Risk Factors for HCC Development**
Eric Letouzé, PhD (France)
- 09:30 – 10:15 **State-of-the-Art Lecture 1: The Scientific Basis of Immunotherapy**
Speaker: Hervé Fridman, PhD (France)
- 10:15 – 10:45 **Coffee and Networking Break**
- 10:45 – 11:00 **Welcome Address**
Richard Finn, MD (USA), Jessica Zucman-Rossi, MD, PhD (France), Bruno Sangro, MD, PhD (Spain) and Morris Sherman, MD, PhD (Canada)
- 11:00 – 12:30 **General Session 1**
- 12:30 – 12:45 **Session Break**
- 12:45 – 14:15 **Diamond Partner Lunch Symposium**
- 14:15 – 14:30 **Session Break**
- 14:30 – 16:00 **General Session 2**
- 16:00 – 16:30 **Coffee and Networking Break**
- 16:30 – 18:00 **ILCA Symposium 2: The HCC-Cholangiocarcinoma Spectrum**
- **Primary Liver Carcinomas: Not Just Two**
Elizabeth Brunt, MD (USA)
 - **HCC-Cholangiocarcinoma and Mixed Tumours: a Molecular Continuum?**
Josep M. Llovet, MD (Spain/USA)
 - **Diagnosis of Hepatocholangiocarcinoma at Imaging**
Kevin Kim, MD (USA)
 - **Cholangiocarcinoma: New Innovative Treatments**
Juan Valle, MD (United Kingdom)
- 18:00 – 18:45 **Welcome Reception**

Saturday, 16 September 2017

- 07:30 – 08:30 **Industry Partner Symposium**
- 08:30 – 10:00 **General Session 3**
- 10:00 – 11:00 **e-Poster Viewing Tour and Networking Break**
- 11:00 – 12:30 **Plenary Session**
- 12:30 – 12:45 **Session Break**
- 12:45 – 13:30 **ILCA Special Interest Groups (SIGs) Luncheon Workshops**
- **SIG Molecular Classification and Signalling Pathways Molecular Classification and Key Drivers of Intrahepatic Cholangiocarcinoma**
Xin Wei Wang, PhD (USA)
 - **SIG Surveillance, Biomarkers and Molecular Pathology Precision Screening for Hepatocellular Carcinoma: Hope or Hype**
Amit Singal, MD (USA)
 - **SIG Liver Surgery and Transplantation**
Katsuhiko Yanaga, MD, PhD (Japan)
 - **SIG Imaging and Loco-Regional Therapies**
Riad Salem, MD (USA)
 - **SIG Target and Systemic Therapies Sequencing and Novel Therapy for Advanced HCC**
Joong-Won Park, MD, PhD (Republic of Korea) and Tim Meyer, MD, PhD (United Kingdom)
 - **SIG Non-HCC Hepatic Malignancies Update of Biomarker Development in Cholangiocarcinoma**
Shahid A. Khan, MD, PhD (United Kingdom)
- 13:30 – 14:00 **Coffee and Networking Break**
- 14:00 – 15:30 **General Session 4**
- 15:30 – 17:00 **ILCA Symposium 3: ILCA and Korea: Innovation in HCC for Diagnosis and Treatment**
- **Innovation in Radiation Therapies on HCC**
Jinsil Seong, MD, PhD (Republic of Korea)
 - **Current Emerging Issues in Diagnosis of HCC**
Jeong Min Lee, MD (Republic of Korea)
 - **Innovation in HCC Resection**
Eric Vibert, MD, PhD (France)
 - **Next Steps in Systemic Therapy: Novel Combination Approaches**
Andrew X. Zhu, MD, PhD (USA)
- 17:00 – 18:00 **Industry Partner Symposium**

Sunday, 17 September 2017

- 08:30 – 09:15 **ILCA General Assembly**
- 09:15 – 10:15 **Industry Partner Symposium**
- 10:15 – 10:45 **Coffee and Networking Break**
- 10:45 – 11:30 **State-of-the-Art Lecture 2: Novel Frontiers in Hepatocellular Carcinoma Surgery**
Speaker: Norihiro Kokudo, MD, PhD (Japan)
- 11:30 – 13:00 **General Session 5**
- 13:00 – 13:15 **Closing Ceremony**

Registration

Registration must be completed online at www.ilca2017.org

Conference Registration Fees

	Early registration 5 June 2017	Late registration 28 August 2017	Onsite fee As of 29 August 2017
ILCA Member*	€ 350	€ 450	€ 500
ILCA Non-Member	€ 575	€ 625	€ 675
Student, Scientist in training**	€ 150	€ 175	€ 200
Accompanying person***	€ 150	€ 160	€ 170

* Please note that ILCA delegates who have not paid their membership dues by 1 September 2017 will not be granted the reduced registration fee. ILCA member's registration fees will only be available after your application or renewal has been fully processed. To apply for or renew your membership, please visit www.ilca-online.org

** This fee is only available to those students who do not yet have their degree. A copy of your student ID card must be provided upon registration.

*** The accompanying person's registration fee includes entrance to the Welcome Reception and all scheduled coffee breaks and lunches.

Cancellation and Refund Policy:

Until 28 August 2017: a € 50 cancellation fee will be applied to process the refund of registration fees.

As of 29 August 2017: no refund of registration fees will be possible.

All refunds are subject to prevailing exchange rates. Refunds will be made following the conference in the same manner as the original payment was received. If bank charges apply, they will be deducted from the refunded amount.

Venue

The venue for ILCA 2017 is the **Grand Hyatt Seoul**. Overlooking the Han River and surrounded by the Mount Namsan nature preserve, this luxury hotel is an 8-minute walk from the Itaewon shopping area and a 6-minute walk from the nearest subway stop.

Reserved rooms at the Grand Hyatt Seoul with specially reduced rates for ILCA 2017 participants are available.

Please visit the www.ilca2017.org website for further information.

Join and Participate in ILCA

Membership in ILCA provides you with exclusive benefits:

- Join a network of international liver cancer experts
- Participate in ILCA scientific events at a preferred rate
- Access the latest information on liver cancer related news and initiatives
- Get involved in association affairs and Special Interest Groups
- Benefit from grants to support your research and enhance your career

Your membership is also essential to support ILCA's initiatives and to help progress its mission to advance research in the pathogenesis, prevention, and treatment of liver cancer. We invite you to discover more about ILCA's initiatives and to connect with our expanding group of liver cancer experts from various fields and from around the world.

To join ILCA and participate in its initiatives, please visit www.ilca-online.org

ILCA Governing Board

Executive Committee

President

Richard Finn (USA)

Executive Secretary

Jessica Zucman-Rossi (France)

Treasurer

Bruno Sangro (Spain)

President Elect

Morris Sherman (Canada)

Council

Sandrine Faivre (France)

Norihiro Kokudo (Japan)

Joong-Won Park (Republic of Korea)

Maria Reig (Spain)

Riad Salem (USA)

Peter Schirmacher (Germany)

Myron Schwartz (USA)

Xin Wei Wang* (USA)

* Liaison in an advisory capacity without fiduciary duties

www.ilca2017.org • www.ilca-online.org

Pre-Conference Workshop on Intermediate Stage Hepatocellular Carcinoma

Thursday, 14 September 2017

Registration fees	
ILCA Member*	€ 125
ILCA Non-Member	€ 150

To attend this workshop, full conference registration is compulsory.

Objectives:

- Identifying patients and tumour characteristics that define this tumour stage and the heterogeneity in terms of tumour biology and prognosis
- Evaluating the challenges for clinical trial design specific to this stage
- Analysing the scientific evidence supporting the use of loco-regional and systemic therapies for patients in this stage of disease

Hotel rates at Grand Hyatt Seoul

Grand Room (single occupancy)	KRW 240,000*
Grand Room (double occupancy)	KRW 285,000*

*Room rate does include breakfast but excludes service charge and government tax.

Contact us
International Liver Cancer Association (ILCA)
Boulevard du Souverain, 280
B-1160 Brussels – Belgium
Tel: +32 2 789 2345
Fax: +32 2 743 1550
Email: info@ilca-online.org
Website: www.ilca-online.org

